© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Roxadustat’s story began within labs searching for better ways to tackle chronic kidney disease-related anemia. Traditional approaches like recombinant human erythropoietin gave hope but came with sharp limitations. Innovators sought drugs that could simulate the body’s natural response to low oxygen without swinging the pendulum too far toward risk. Scientists behind Roxadustat zeroed in on the hypoxia-inducible factor (HIF) pathway, which controls how the body creates red blood cells under oxygen stress. Years of trial and error, setbacks in animal trials, and long regulatory bottlenecks marked the road. The translational leap didn’t come easy; the complexity of the HIF pathway made each curveball in early clinical trials matter. Approval in China, Japan, and eventually other regions signaled a shift. Now, several years past its original release, Roxadustat stands as a solid illustration of targeted pharmaceutical innovation that didn’t just stop at the bench, but made a mark in hospital wards and patient circles.
At its core, Roxadustat is an orally administered small molecule. It’s used to treat anemia in chronic kidney disease patients—both on dialysis and not. For healthcare professionals, one of the big attractions is the oral route, which sidesteps issues that often dog injectable forms, like storage headaches or needle-related complications. Roxadustat works by blocking oxygen sensors in the body, tricking cells into believing there’s not enough oxygen. This drives up natural erythropoietin production and revs up the machinery that helps the body pick up and use iron to build new blood cells. Patients notice practical improvements: fewer transfusions, less fatigue, a route that fits daily life rather than medical appointments.
Look inside a jar of Roxadustat and you’ll find a crystalline powder, usually white to pale yellow. It doesn’t dissolve well in water, but shows better solubility in DMSO and other common lab solvents. Its melting point sits above 200°C, giving some leeway on storage. Chemically, Roxadustat holds a molecular formula of C19H16N2O5, and has a molecular weight near 352.35 g/mol. Its structure reveals several functional groups—most critically, a heterocyclic ring and a couple of key oxygen and nitrogen atoms that bind to the HIF prolyl hydroxylase enzyme. These groups underpin both its effectiveness and most off-target effects. Handling it in bulk form brings some dust concerns, but careful environmental controls make large-scale processing feasible.
A bottle of Roxadustat tablets will often show strengths ranging between 20 mg and 100 mg. The labeling usually details the recommended dosing schedule, which adapts to a patient’s weight, iron status, and hemoglobin targets. The product’s information sheet outlines contraindications, common drug interactions, and careful advice regarding liver or cardiovascular risks. Quality specifications focus on purity, water content, related compound levels, and physical uniformity. Each batch flows through strict analytical testing: HPLC profiles, solubility measurements, and impurity checks dominate the process. Manufacturers must meet International Conference on Harmonisation (ICH) guidelines for stability and packaging. Tamper-proofing on commercial packages protects the public from misuse and supports traceability.
Sourcing Roxadustat for commercial use usually involves several chemical steps. Starting with custom-synthesized heterocyclic intermediates, the synthesis moves through coupling, cyclization, and functionalization. Key challenges sit in the formation of the pyridine and quinoline rings, both necessary for its biological punch. Modern processes limit the use of harsh reagents and scale up efficiently, in part thanks to decades of accumulated experience in heterocycle chemistry. Rigorous purification by recrystallization or chromatography strips out unwanted isomers and side-products, bringing the final product into line with pharmacopeial standards. The waste streams draw environmental scrutiny, so responsible manufacturers invest heavily in clean-up and recycling, keeping both costs and local ecosystems in check.
Roxadustat’s chemical configuration means it’s ripe for diverse reactions. Active research groups modify the ring system to probe for better selectivity or longer action, using acylation, alkylation, or even halogenation. Protecting groups get added and removed during key steps, helping shepherd the molecule through multi-stage synthesis. When stressed with acids or bases, Roxadustat holds together fairly well, showing why it survives the stomach’s acidity. In metabolic studies, the molecule shows predictable breakdown via oxidative and reductive pathways, mostly through liver enzymes. These findings steer formulation tweaks aimed at controlling release rates or blunting unwanted metabolites.
Folks tracking Roxadustat across journal articles, clinical trials, or supply chains will run into a stack of synonyms. The most common is the development code FG-4592, a hangover from its earliest reports. On pharmacy shelves it’s often branded as Evrenzo or Azenna in different regions. Chemically minded users sometimes refer to its full IUPAC name, which is a mouthful and rarely used outside regulatory submissions. Each synonym points back to one compound—clarity here keeps prescribing errors and shipment snafus at bay. Pharmacists and supply chain managers rely on cross-references daily to ensure the drug in the bottle matches what the doctor expects.
People working with Roxadustat keep a careful eye on safety data. Direct contact with the powder can irritate skin or mucous membranes, so gloves and goggles count as standard gear. Facility air handling catches airborne dust and stops cross-contamination. Disposal of excess or expired product follows clear hazardous-waste rules. On the patient side, safety reviews focus on cardiovascular effects, potential clot risks, and the chance of exacerbating pre-existing malignancies. These concerns drive ongoing monitoring during use, especially in high-risk populations. Standardized operating procedures line out touchpoints for hospital and clinical staff to report adverse events, reinforcing early warnings.
The biggest slice of Roxadustat’s impact lands in the chronic kidney disease community. Here, the drug offers a route toward more stable hemoglobin control, translating to fewer hospital trips and transfusion needs. Nephrologists see a practical uptick in treatment adherence compared to injectables—patients simply stick with a tablet regimen better. Ongoing trials look for new application areas, such as treating chemotherapy-induced anemia, inflammatory conditions, and possibly rare genetic conditions that disrupt oxygen sensing. These uses stay under the microscope, but the science behind Roxadustat opens a door to broader indications if future studies pan out.
Roxadustat’s initial clinical success spawned a new generation of interest in HIF pathway activators. Research teams race to find analogs with longer duration or cleaner side-effect profiles. Medicinal chemists dissect how small tweaks in the core structure might build drugs that treat other hypoxia-linked conditions, like heart failure or pulmonary hypertension. Funding pours in from public and private sources, fueling investigations into population-specific efficacy, optimal dosing for different ethnic groups, and combination therapy potential. Academic centers produce a steady stream of real-world evidence to guide post-marketing safety reviews and push regulators to fine-tune labeling.
The safety work that got Roxadustat past regulators was anything but superficial. Animal models mapped out side-effect risks, especially at doses many times higher than the clinical norm. Cardiotoxicity, changes in cancer risk, and reproductive toxicity got special scrutiny. Human trials flagged some increases in blood pressure and clotting events, so prescribers have to keep tabs on susceptible patients. Post-marketing surveillance digs through reports of strange or unexpected side effects. This vigilance keeps treatment benefits in focus while shining a flashlight on any developing safety trends. Transparent reporting from both the clinic and the lab shores up public trust, especially as new populations get exposed to the drug.
The journey for Roxadustat didn’t wrap up with its first regulatory nod. Pharmaceutical leaders treat this drug as a proof-of-concept for broader HIF-targeted therapies, with hopes pinned on derivatives reaching into new diseases. Generic manufacturers in India, China, and beyond line up to make cost-effective copies, promising wider access for patients in middle- and low-income countries. Advocacy groups push for robust long-term data, ensuring health systems keep treatment affordable and safe as guidelines evolve. Meanwhile, next-gen molecules build on Roxadustat’s blueprint, aiming for oral drugs with less toxicity, even more convenient dosing, and new uses in medicine. This chapter isn’t closing anytime soon; industry watchers and patients alike keep a clear eye on how this class of drugs shapes both everyday care and the next breakthroughs in organ protection and chronic disease management.
Roxadustat comes into play for adults fighting anemia triggered by chronic kidney disease (CKD). People with CKD often struggle with fatigue, weakness, and shortness of breath. These symptoms don’t just slow folks down; they take a toll on overall health. From what I’ve seen working around patients and hearing from healthcare providers, anemia has real consequences — not just for energy but for the ability to recover from illness, work, socialize, or enjoy simple things like playing with grandchildren.
This oral medicine stirs up the body’s own ability to produce red blood cells. The main challenge with CKD is that damaged kidneys stop making enough erythropoietin, a hormone that lays the groundwork for red blood cell production. Taking Roxadustat encourages the body to kickstart that process. Unlike the old injections, Roxadustat gets swallowed, which makes life easier for people who would otherwise line up for shots every week in a dialysis center.
In the past, anemia treatment for CKD leaned heavily on synthetic erythropoietin injections plus regular iron supplements. Trouble is, these injections can spark high blood pressure, heart problems, or even increase the chance of stroke. Roxadustat’s different — it nudges the body to respond in a more balanced way, acting like a low-oxygen signal that the body would get at higher altitudes or in times of need.
People on dialysis are always juggling pills, appointments, and dietary rules. Anything that takes one more needle out of the routine feels like a relief. For folks who haven’t started dialysis yet, early anemia treatment can keep them strong longer and delay some of the worst complications.
No medicine comes without concerns. Roxadustat isn’t a miracle fix. Side effects like high blood pressure, too much potassium in the blood, or headaches can pop up. Some doctors haven’t completely bought in yet because long-term data is still building. The U.S. Food and Drug Administration didn’t move as quickly as some countries to approve it, pointing to questions about heart risks and safety. Europe and China have seen broader use, and as more data rolls in, trust in this option seems to be slowly growing.
Cost is another story. New drugs usually demand a higher price, which creates challenges for people with limited insurance or those relying on government programs. In my view, real improvement for patients means giving everyone who needs it a fair shot at trying Roxadustat — not just those with top-tier insurance.
Doctors, nurses, and patients need straight talk about what to expect with Roxadustat. That means open conversations about risks, benefits, and how this medicine fits with lifestyle or other prescriptions. Regulators and researchers should share findings in clear language — not medical jargon that makes folks tune out. From my time supporting families through chronic illness, I can say nothing builds trust like honesty about what a treatment can or can’t do.
Governments and insurers should negotiate fair prices so this isn’t another medicine that only a few can afford. Hospitals and clinics benefit from educational programs that help staff spot early warning signs when things go sideways. Investment in ongoing research helps build a clearer, safer roadmap for the future. That’s how Roxadustat stands a real chance to level the playing field for people dealing with the day-to-day grind of chronic kidney disease and anemia.
Roxadustat tackles anemia in kidney disease by waking up the body’s natural response to low oxygen. The medicine doesn’t supply iron or replace missing hormones the way older treatments do. Instead, it encourages the body to make more of its own hormone called erythropoietin (EPO). Unlike traditional EPO shots that flood the system, Roxadustat nudges the kidneys and liver into making the right amount at the right time.
People with kidney problems often struggle to keep up with regular injections or feel worn out from iron pills that don’t always agree with their stomach. Roxadustat comes as a pill, bringing with it a real chance for folks to handle their anemia from home. For many, that switch means fewer trips to the clinic—something I’ve seen make a world of difference for patients trying to get back pieces of normal life like work, family dinners, or hobbies.
Roxadustat blocks enzymes called prolyl hydroxylases. These enzymes usually mark the body’s oxygen-sensing proteins, also known as HIF proteins, for destruction. When those proteins hang around longer, they activate genes that fight low oxygen—boosting red blood cell production and helping the body gather and use iron more effectively. Researchers saw this as a way to mimic the effects of climbing to a higher altitude, where people’s bodies get used to thinner air by churning out more red blood cells.
Studies show Roxadustat gets those red blood cells up even in patients who have trouble absorbing iron or those with chronic inflammation. In fact, the medicine helps the body absorb more iron from food and move it out of storage—two big hang-ups that often block progress for kidney patients.
No one wants a medicine that brings surprise problems. Some old EPO treatments led to higher rates of stroke or heart attack, especially if folks pushed their red blood cell counts too high. Roxadustat doesn’t force the body the same way, but questions still remain. Researchers have seen some shifts in potassium levels and blood pressure, so regular check-ins still matter a lot. The pill also poses some unknowns for people with certain cancers since boosting the same pathways that heal anemia could feed tumor growth.
It’s easy for doctors and scientists to get wrapped up in lab results and numbers. The real story shows up in daily life. Fatigue from anemia saps energy, dulls thinking, and makes simple chores a struggle. I’ve watched patients reclaim energy and hope with newer treatments that don’t chain them to a hospital chair or endless iron infusions.
No single pill solves every case of anemia or fits all bodies. Roxadustat offers a new tool, but it takes teamwork between healthcare staff and patients to spot side effects early and fine-tune doses. Doctors who listen closely and adjust treatment plans can help more people gain both freedom and strength. On a bigger scale, more research into which patients benefit most will drive better results with fewer risks. For anyone struggling with chronic kidney disease, advances like this bring more than just higher lab numbers—they offer real momentum toward living life fully again.
Roxadustat landed as a new option for people with anemia linked to chronic kidney disease. With an oral alternative in a field dominated by injections, lots of patients and doctors welcomed it. Still, every pill carries more than just its promise. Knowing the side effects shapes real-world decisions at the pharmacy and clinic.
Some people taking Roxadustat experience headaches, fatigue, or dizziness. It’s pretty familiar territory for anyone who has dealt with new medications. Nausea comes up in the talk, sometimes enough to interfere with meals or routines. Diarrhea joins the list, less common but enough to be mentioned in studies. High blood pressure can crop up for some, which matters if a person already tracks numbers at home.
My time in community health showed that even mild side effects change how well someone sticks with a medicine. Nobody wants to spend daily life wrestling with headaches or trips to the bathroom. Having an honest conversation about these basic discomforts respects the hassles patients actually face.
Roxadustat isn’t free from bigger worries. Some folks face a higher risk of blood clots, such as deep vein thrombosis or pulmonary embolism. For anyone already carrying risk factors—immobility, a history of clotting problems—this side effect isn’t just a line in fine print. Studies, including Phase III trials published in NEJM, underscore the need for caution, particularly as higher hemoglobin targets get reached faster than with older drugs.
People sometimes see their potassium rise, a real problem for those with failing kidneys. Hyperkalemia can sneak up and cause muscle weakness or—worst case—heart rhythm changes. Reports also mention an increased risk of infections, mostly upper respiratory types. For immunocompromised patients, every cough matters.
Side effects don’t just exist on paper. They shape whether someone calls a doctor, changes habits, or worries through the night about new symptoms. In places with less health literacy, someone might stop a needed medication over mild nausea, not knowing that side effects fade or can be managed. Or people tough it out through dangerous symptoms, thinking ‘it’s just part of the process,’ because no one stressed what to watch for.
Doctors and nurses rely on real information, not just published averages. Some people breeze through Roxadustat with no trouble at all, while others land in the emergency room with a blood clot. This unpredictability means the decision to use Roxadustat stays personal, weighing the punch anemia packs against the risks carried by the new pill.
Staying safe starts with clear communication. Providers need to lay out the likely, the rare, and the downright scary in plain language. Bloodwork can catch changes in potassium and hemoglobin before they snowball. Checking blood pressure at home—something most folks can do with a drugstore cuff—helps patients stay ahead of possible spikes. For those with a clotting history, alternatives might still work better.
Pharmacists play a role by offering side effect handouts and tips, not just doling out bottles. Families can help with reminders or by watching for new symptoms, especially when someone can’t self-advocate. Reporting side effects to agencies like the FDA ensures the bigger picture grows clearer for future patients.
Making medication choices isn’t just about efficacy. It’s about balancing risk, comfort, and quality of life—especially when living with a chronic illness demands everything someone has to give.
Doctors use Roxadustat to treat anemia in adults with chronic kidney disease. For some, this medicine helps reduce the grind of tiredness and breathlessness that comes from low red blood cell counts. But not every medicine fits every patient, and Roxadustat brings its own set of risks. Ignoring the details can cost a patient much more than a wasted prescription.
Blood pressure up out of control signals real trouble for folks looking at Roxadustat. Studies hint that this drug can push blood pressure higher. For someone already wrangling stubborn hypertension, tossing Roxadustat into the mix only makes the situation riskier. Blood vessels and hearts don’t always handle pressure spikes well, and strokes or heart attacks aren’t far behind.
Some people know what it’s like to break out in hives or struggle to breathe after a new medicine. Roxadustat, like many drugs, can trigger rough allergic reactions. Tight chests, swelling, or serious skin rashes mean a person has to steer clear. Once an allergy shows up, sticking with it invites real harm.
Roxadustat works by helping the body churn out more red blood cells. Here’s the catch: some cancers thrive on extra blood supply. Studies suggest that certain tumors could tap into this output, growing faster or even spreading more easily. Anyone with active cancer or a history of tumors should talk it out with a specialist instead of assuming this anemia treatment is safe.
My own family has seen the havoc liver disease can bring. Medicines pile up in the bloodstream when the liver can’t break them down. Roxadustat isn’t gentle on a struggling liver. Large studies haven’t explored enough, but doctors know that any medicine processed through the liver raises the risk of toxic effects in people with cirrhosis or serious liver damage.
Moms-to-be want to keep risks close to zero. Roxadustat hasn’t earned any safety stars during pregnancy or while nursing. Animal studies point to problems without offering real guarantees for humans. I remember a close friend who weighed this kind of choice for another medicine—uncertainty led her to wait. With little hard proof of safety, keeping a safe distance looks smart.
Clear conversations between patients and their doctors prevent a lot of drama. Blood pressure gets checked and double-checked. People with cancer histories talk to oncologists before starting anything new. Keeping updated medication lists on hand pays off if allergies or liver problems pop up. Families should speak up about pregnancy plans. These steps lower the chance of taking a drug that does more harm than good.
Information from trusted organizations like the FDA and peer-reviewed studies always guides safe choices. Trusted doctors bring wisdom from treating many patients, not just textbook answers. Roxadustat can help some folks, but not everyone. Knowing who should skip this medicine protects lives beyond what a quick web search or a rushed appointment might reveal.
Having followed advances in kidney disease treatment, I’ve watched Roxadustat gather both hope and scrutiny from patients and clinicians. Roxadustat helps treat anemia in chronic kidney disease by stimulating the body’s own production of the hormone erythropoietin. For people constantly tethered to clinics for injections or feeling worn out by anemia’s fatigue, Roxadustat promises a once-tablet alternative that fits into daily life.
Regulatory authorities don’t always agree. In China, Roxadustat broke ground years ago, winning approval in 2018 from the National Medical Products Administration to help both dialysis and non-dialysis kidney disease patients. Other countries in Asia and Latin America took China’s cue, seeing not only a new drug, but relief for people whose access to healthcare might be limited by travel or financial barriers. Japan also accepted Roxadustat, taking a stance that reflects a robust appetite for innovation in treating kidney conditions.
Going west paints a different picture. The European Medicines Agency walked a cautious path, approving the drug in 2021 under the name Evrenzo but asking doctors to keep a close watch for cardiovascular risks. The United States Food and Drug Administration, though, remains unconvinced. The FDA’s panel raised concerns about safety, pointing to higher rates of heart-related side effects. For American patients, that means waiting longer for new anemia treatments while options remain stuck on iron supplements and ESA injections.
The divide among regulators tells a bigger story about balancing medical need against possible harm. Many U.S. nephrologists want new tools, but history has taught caution. Drugs like erythropoiesis-stimulating agents boosted red blood cells but brought unanticipated dangers. Medical trust runs deep; once lost, it comes back slowly. And every approval or denial plays out in the exam rooms and homes of real people, not just clinical trial reports.
From my own experience talking with kidney patients, people crave options, not just because of a dislike for needles, but because side effects from current treatments throw up their own headaches: unstable blood pressure, hospital visits, life interrupted. Treatments that fit into life and respect dignity are always worth fighting for.
Fixing the regulatory puzzle calls for better clinical data. Longer studies help uncover who stands to benefit the most and who faces the most risk. Open access to trial results builds public confidence in whatever decision is made. In places where Roxadustat is already available, hospitals and doctors track outcomes and share findings — real-world data often shines brighter light than controlled trials alone.
Bridging the gap between regulators means sharing not just facts, but experience: how Roxadustat fits into care, what unexpected issues pop up, how patients actually feel after taking it. Medical progress isn’t handed down; it grows from ongoing trust between patients, doctors, and authorities. That trust depends on honest risks being discussed out loud, real benefits being measured, and everyone rooting their arguments in what actually happens to real people’s lives.
| Names | |
| Preferred IUPAC name | N‐(4‐hydroxy‐1‐methyl‐7‐(phenoxy)isoquinolin‐3‐yl)carboxamide |
| Other names |
FG-4592 Evrenzo |
| Pronunciation | /ˌroʊk.səˈdʌs.tæt/ |
| Identifiers | |
| CAS Number | 808118-40-3 |
| Beilstein Reference | 4220664 |
| ChEBI | CHEBI:134722 |
| ChEMBL | CHEMBL2103885 |
| ChemSpider | 20886644 |
| DrugBank | DB12510 |
| ECHA InfoCard | 07b3a0e7-17d3-40c7-bff3-a5237c43c117 |
| EC Number | 4.1.3.28 |
| Gmelin Reference | 1685171 |
| KEGG | D09367 |
| MeSH | D000077633 |
| PubChem CID | 12209938 |
| RTECS number | GG28Y47V5F |
| UNII | 3127HFU8ZB |
| UN number | UN3549 |
| CompTox Dashboard (EPA) | DTXSID30898647 |
| Properties | |
| Chemical formula | C19H16N2O5 |
| Molar mass | 262.239 g/mol |
| Appearance | White to yellowish-white powder |
| Odor | Odorless |
| Density | 1.45 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 1.49 |
| Acidity (pKa) | 8.34 |
| Basicity (pKb) | 8.92 |
| Refractive index (nD) | 1.482 |
| Dipole moment | 2.9421 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 354.2 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -302.1 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -680.2 kJ·mol⁻¹ |
| Pharmacology | |
| ATC code | B03XA05 |
| Hazards | |
| Main hazards | May cause cancer, may damage fertility or the unborn child, harmful if swallowed, causes damage to organs through prolonged or repeated exposure. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | ❌💉🚫🧒🤰 |
| Signal word | Warning |
| Hazard statements | H360fd: May damage fertility. May damage the unborn child. |
| Precautionary statements | Keep out of reach of children. |
| Flash point | > 648.1 °C |
| Lethal dose or concentration | LD50 (rat, oral): > 2000 mg/kg |
| LD50 (median dose) | > 100 mg/kg (Rat, Oral) |
| PEL (Permissible) | Not established. |
| REL (Recommended) | 100 mg |
| IDLH (Immediate danger) | NIOSH has not established an IDLH value for Roxadustat. |
| Related compounds | |
| Related compounds |
Daprodustat Vadadustat Desidustat Molidustat |
